Employers have long played a critical role in shaping health benefits, but today’s policy and market shifts are amplifying their influence in new ways. Recent reforms focused on PBM transparency, fiduciary accountability and pricing structures are giving employers greater visibility into how pharmacy benefits are designed, managed and evaluated. With that visibility comes increased opportunity, and expectation, for employers to ask harder questions about how benefit design can better support affordability, access and value for their workforces.

Broader industry disruption is further accelerating this trend. As new direct-to-employer and direct-to-patient access models emerge and scrutiny around cost and value intensifies, employers are becoming more central to how therapies are assessed and ultimately covered.

This shift won’t look the same across the market. Larger, more sophisticated employers may take a more hands-on role in shaping benefit design, formulary decisions and PBM relationships. Others may continue to rely on trusted partners, consultants or employer coalitions. Many employers may increasingly ask for data to help them determine whether utilization management is justified, whether out-of-pocket costs align with value or whether coverage decisions support workforce health in the long term.

The direction is clear: employer influence is growing and increasingly consequential.

For innovators, this evolution underscores the need for a more intentional approach to employer engagement. Traditional market access strategies have focused on health plans and PBMs, but employers bring a distinct perspective that warrants dedicated approaches. Their decision-making is often grounded in a broader view of value, one that balances total cost of care, employee affordability, workforce continuity, productivity, disability trends, retention and long-term health outcomes.

This creates both a challenge and an opportunity. Companies bringing new therapies to market must rethink how they develop evidence, communicate value and engage stakeholders, ensuring that their approach resonates with how employers assess trade-offs and make benefits decisions. Clear, relevant and practical insights — particularly those that connect clinical value to real-world workforce impact — will be critical. Employer engagement cannot simply rely on a repurposed payer narrative. It will require a tailored understanding of employer priorities, evidence that connects therapeutic value to workforce needs and education that meets benefits decision-makers where they’re at and through the channels and resources they already rely on.   

What Innovators Need to Build Now

To prepare for this shift, innovators need to develop a more nuanced understanding of how benefits leaders assess value, affordability and workforce impact. This requires listening to employers directly; understanding how coalitions, benefits consultants and purchaser organizations shape benefit priorities; and translating clinical and economic evidence into insights that are relevant to benefits decision-making.

Having an integrated access strategy can be especially valuable. Companies should consider how employer perspectives are reflected across market research, evidence generation, value communications, stakeholder engagement and education. Practical areas of focus could include:

• Investing in actionable employer insights by engaging benefits leaders and employer coalitions to better understand the priorities and decision drivers shaping coverage decisions;
• Developing employer-relevant evidence and analytics grounded in the outcomes employers care about most, including total cost of care, affordability and workforce productivity;
• Building strategic engagement approaches that connect with the organizations and stakeholders influencing employer benefit design and broader market trends; and
• Delivering targeted education initiatives that provide credible, decision-relevant information through the channels and voices employers trust most.

The goal is not to “market” to employers in a traditional sense, but to ensure that employers have credible, practical information that helps them assess whether benefit design supports access, affordability and better health outcomes.

As employers play an increasingly influential role in access decisions, innovators that proactively build employer-focused strategies into their market access approach will be best positioned to anticipate scrutiny, support more informed benefits conversations and build trust with stakeholders. In this new era, access strategy must account not only for how therapies are covered, but for how coverage decisions are understood, justified and trusted by the organizations responsible for delivering benefits to millions of Americans.